The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
-
BUSINESS Novartis Japan to Shed Oncology Staffers amid Overall Downscaling
March 24, 2020
-
ACADEMIA Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
-
BUSINESS Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
-
REGULATORY Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
-
BUSINESS (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
-
ACADEMIA Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
-
BUSINESS Post-Promotion Guidelines - 1: Drug Makers Struggling to Establish Non-Sales Criteria for Rep Performance Review
March 18, 2020
-
BUSINESS Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
-
ORGANIZATION Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
-
BUSINESS Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
-
COMMENTARY Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?
March 12, 2020
-
BUSINESS Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
-
REGULATORY Japan Cabinet OKs Bill to Allow Govt to Declare Emergency over Coronavirus
March 11, 2020
-
BUSINESS Japan’s 2020 Price Revision Hits Major Drugs with Double-Digit Slashes: Top 5 Product Survey
March 10, 2020
-
BUSINESS Japan’s Big 3 Generic Makers See 12.2% Price Cut vs. FY2018: Jiho Poll
March 9, 2020
-
BUSINESS Chugai, Teijin Suffer Hefty 9% Cuts in 2020 Drug Price Revision: Jiho Poll
March 6, 2020
-
REGULATORY Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
-
BUSINESS Sumitomo Dainippon Creates Chief Scientific Officer Post to Optimize Portfolio
March 4, 2020
-
BUSINESS Vital-Net to Create 20-Strong Team of “Regenerative Medicine Liaisons”
March 3, 2020
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…